Results 1 to 10 of about 30,965 (227)
Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib [PDF]
BMC MedicineBackground Sunitinib is an orally administered novel multi-targeted therapy for treating tumors especially for gastrointestinal stromal tumors and metastatic renal cell carcinoma (RCC) but associated with cardiovascular toxicity.
Shi-yu Huang +7 more
doaj +2 more sources
Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity
Anatolian Journal of Cardiology, 2023 Background: Doxorubicin is a widely used agent in the treatment of cancer, but the cardiotoxicity associated with this drug limits its potential for use.
Sebahat Ulusan +5 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Dapagliflozin has been used to treat patients with type 1 diabetes mellitus; however, the actual drug efficacy of dapagliflozin on glycated hemoglobin (HbA1c) and whether there is a rebound from dapagliflozin efficacy on HbA1c remain unknown. The present
Dong-Dong Wang +5 more
doaj +1 more source
Hospital Pharmacy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +2 more sources
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
Scientific Reports, 2021 The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome.
Lan Cheng +8 more
doaj +1 more source
Kidney & Blood Pressure Research, 2023 Introduction: This study aimed to investigate the effect of dapagliflozin in preventing post-contrast acute kidney injury (PC-AKI) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) who underwent an elective coronary procedure ...
Tao Liu +4 more
doaj +1 more source
Frontiers in Endocrinology, 2022 BackgroundMost patients with type 1 diabetes (T1DM) do not reach the blood glucose goal with treatment of insulin. In our research, we intended to estimate the therapeutic effect and safety of additional different doses of dapagliflozin on insulin ...
Yinhui Li +8 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 Background: The sodium-glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin improves cardiovascular outcomes in patients with type 2 diabetes in a manner that is partially independent of its hypoglycemic effect.
Yong-Wei Yu +11 more
doaj +1 more source
Biomedicines, 2023 Increases in numerical chromosomal syndromes were observed in children of diabetic mothers. However, the effects of diabetes on male reproduction, specifically numerical chromosomal aberrations (aneuploidy), have not been studied.
Norah A. Albekairi +8 more
doaj +1 more source
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. [PDF]
PLoS ONE, 2016 Dapagliflozin, a new type of drug used to treat diabetes mellitus (DM), is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Although some studies showed that SGLT2 inhibition attenuated reactive oxygen generation in diabetic kidney the role of SGLT2 ...
Yoon-Kyung Chang +6 more
doaj +1 more source